Fox Run Management’s TG Therapeutics TGTX Stock Holding History

Fox Run Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$580K	Buy	+10,560	New	+$432K	0.1%	413
2025 Q3	–	Sell	-9,832	Closed	-$354K	–	1231
2025 Q2	$354K	Sell	9,832 -9,171	-48%	-$341K	0.06%	596
2025 Q1	$749K	Buy	+19,003	New	+$639K	0.12%	307
2024 Q2	–	Sell	-50,724	Closed	-$772K	–	1077
2024 Q1	$772K	Buy	50,724 +23,061	+83%	+$367K	0.17%	224
2023 Q4	$472K	Buy	27,663 +11,884	+75%	+$138K	0.12%	329
2023 Q3	$132K	Buy	+15,779	New	+$220K	0.04%	607
2023 Q2	–	Sell	-25,736	Closed	-$387K	–	956
2023 Q1	$387K	Buy	+25,736	New	+$391K	0.13%	316
2018 Q2	–	Sell	-16,738	Closed	-$238K	–	911
2018 Q1	$238K	Buy	+16,738	New	+$214K	0.06%	575
2017 Q3	–	Sell	-15,500	Closed	-$156K	–	860
2017 Q2	$156K	Buy	+15,500	New	+$173K	0.05%	570
2017 Q1	–	Sell	-18,600	Closed	-$86K	–	745
2016 Q4	$86K	Buy	+18,600	New	+$109K	0.05%	473

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Fox Run Management's TGTX Position: Q2 2026 in Review

Fox Run Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 10,560 shares worth $580K. The stake represents 0.1% of the portfolio and ranks #413 among its holdings. This is a return to the name: Fox Run Management previously reported a position in TGTX as recently as Q2 2025.

Fox Run Management first reported a position in TGTX in Q4 2016 and has held it in 10 quarters since. The position peaked at $772K in Q1 2024. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Fox Run Management held 10,560 shares of TG Therapeutics worth $580K as of Q2 2026.
TG Therapeutics was a new Fox Run Management position in Q2 2026.
TG Therapeutics made up 0.1% of Fox Run Management's portfolio in Q2 2026, its #413 holding.
Fox Run Management first reported a position in TG Therapeutics in Q4 2016 and has held it in 10 quarters since.
Fox Run Management's TG Therapeutics position peaked at $772K in Q1 2024.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.